开发复发性肝细胞癌的风险分层策略和生物标志物
Jia-Hao Law1, Huilin Shao2,3,4,5, Ramanuj DasGupta6
1Division of Hepatobiliary & Pancreatic Surgery, Department of Surgery, National University Hospital, Singapore.
Clinical and translational medicine
|July 31, 2025
概括
肝细胞癌 (HCC) 复发是一个重大挑战. 先进的生物标志物和人工智能分析可以改善风险预测和个性化治疗,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 肝病学 肝病学是一种肝病学.
- 翻译医学是一种翻译医学.
背景情况:
- 肝细胞癌 (HCC) 是癌症死亡的主要原因,手术后复发率高.
- 目前的复发预测因素不足以识别高风险患者.
- 肝病的病因正在转向与代谢功能障碍相关的脂肪肝炎 (MASH) 和与酒精有关的肝病.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.5K
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.0K
